NVCR · NovoCure Ltd
$17.77
-0.43 (-2.36%)
At close · Aug 20
Market Cap
$2.12B
Shares
116.45M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.77
Open$18.12
Day$17.48–18.61
52W close$10.03–19.99
Avg vol 30d1.6M
Short int10.1M · 8.7% float · 4.9d
Short vol47%
Last earningsJul 23, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 23
Up next
Next earnings call
Oct 22, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 23, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+27%
above
Price vs 50-day avg
+8%
above
RSI (14)
56
neutral
MACD trend
Positive
52-week position
78%
mid-range
Momentum
relative strength
1-month return
−11%
trailing
6-month return
+30%
trailing
YTD return
+37%
this year
Relative strength
+19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $16 › 200d $14 — 50d above 200d
Institutional flow
Distributing
-5% holders QoQ · +31 funds added
Insider flow
Distributing
Net -$939.7K over 90 days · 100% sells
Short interest
Falling
8.71% of float · ▼ -11.5% MoM · 4.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
214 holders — near 3-yr low, contrarian setup
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
75%
contracting
EPS growth
+22%
Y/Y
Free cash flow
$-75.7M
Balance sheet
$93.4M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 23, 2026
Total net revenue
· full year 2026
Initiated
$710M – $725M
prior FY $655.35M
midpoint +9.5% Y/Y
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2025
Import duties on 2025 cost of goods
· 2025
$11M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+27%
Bullish
Price vs 50-day avg
+8%
Bullish
RSI (14)
56
Neutral
MACD trend
Positive
Bullish
52-week position
78%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $16 › 200d $14 — 50d above 200d
Institutional flow
Distributing
-5% holders QoQ · +31 funds added
Insider flow
Distributing
Net -$939.7K over 90 days · 100% sells
Short interest
Falling
8.71% of float · ▼ -11.5% MoM · 4.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
214 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $10
Now $18 · 78%
Range high $20
vs 200-day avg +27%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Active patients on Optune Gio | 4,636 | Q2 2026 | — |
|
|
|||
| Active patients on Optune Lua | 207 | Q2 2026 | — |
|
|
|||
| Active patients on Optune Pax in the U.S. | 285 | Q2 2026 | — |
|
|
|||
| Prescriptions for Optune Pax received | 418 | Q2 2026 | — |
|
|
|||
| Total active patients on TTFields therapy globally | 5,128 | Q2 2026 | — |
|
|
|||
| Active Optune Lua patients on therapy for the treatment of MPM | 34 | as of December 31, 2025 | — |
| Active Optune Lua patients on therapy for the treatment of NSCLC | 122 | as of December 31, 2025 | — |
| Optune Gio prescriptions received for the treatment of GBM | 1,609 | fourth quarter | — |
| Optune Lua prescriptions received for the treatment of MPM | 27 | fourth quarter | — |
| Optune Lua prescriptions received for the treatment of NSCLC | 118 | fourth quarter | — |
| Total Optune Lua prescriptions received | 145 | fourth quarter | — |
| Total prescriptions for Optune Lua | 145 | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVCR
this stock
NovoCure Ltd
|
$2.12B | +37.4% | +8.3% | — | 8.7% |
|
ABT
Abbott Laboratories
|
$198.81B | -8.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$127.26B | -6.8% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$120.49B | -3.9% | +8.4% | 25.2 | 1.4% |
|
BSX
Boston Scientific Corp
|
$71.55B | -48.2% | +12.5% | 20.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVCR | +2.2% | -11.1% | +30.0% | +19.7% | +37.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +4.2% | -14.4% | +18.8% | +17.7% | +25.6% |
Key facts
CIK
1645113
CUSIP
G6674U108
13F (30d)
221 filings
195 filers
Visit website
Investor relations